Đánh Giá Ngắn Gọn: Yếu Tố Phân Hóa Tăng Trưởng 15 Trong Bệnh Lý: Vai Trò Lâm Sàng?

Stem cells translational medicine - Tập 2 Số 12 - Trang 946-952 - 2013
Jill Corre1,2, Benjamin Hébraud3, Philippe Bourin4
1Hematology Laboratory, University Hospital Purpan, Toulouse, France
2Institut National de la Santé et de la Recherche Médicale (INSERM), U1037, Toulouse, France
3Hematology Department, University Hospital Purpan, Toulouse, France;
4CSA21, Toulouse, France

Tóm tắt

Tóm tắt

Yếu tố phân hóa tăng trưởng 15 (GDF15) là một thành viên khác biệt của họ yếu tố tăng trưởng biến đổi β, được phát hiện trong nhiều loại tế bào, như được chỉ ra bởi sự đa dạng trong việc đặt tên của nó. Tuy nhiên, mô duy nhất thể hiện một lượng lớn GDF15 trong trạng thái sinh lý là nhau thai. GDF15 dễ dàng được phát hiện trong máu, và nồng độ của nó thay đổi theo độ tuổi. Trên thực tế, nồng độ GDF15 trong máu tăng cao liên quan đến nhiều tình trạng bệnh lý. Tuy nhiên, ý nghĩa sinh học cơ sở cho những quan sát này vẫn chưa rõ ràng. GDF15 có thể đóng vai trò tích cực hoặc tiêu cực tùy thuộc vào trạng thái của tế bào hoặc môi trường của chúng. Hơn nữa, việc nghiên cứu sinh học của nó gặp khó khăn do thiếu kiến thức về thụ thể và do đó các con đường tín hiệu điều khiển hoạt động của nó. GDF15 dường như là một tín hiệu tích hợp trong các tình trạng bệnh lý, cung cấp thông tin về mức độ nghiêm trọng của bệnh. Hiệu quả của nó trong việc phân loại bệnh nhân để điều chỉnh điều trị vẫn cần được chứng minh. Việc phát triển các can thiệp trị liệu với GDF15 hoặc các tác nhân chống GDF15 vẫn gặp nhiều khó khăn cho đến khi chúng ta khám phá được cơ chế điều khiển hoạt động của nó.

Từ khóa


Tài liệu tham khảo

Bootcov, 1997, MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-β superfamily, Proc Natl Acad Sci USA, 94, 11514, 10.1073/pnas.94.21.11514

Eling, 2006, NSAID activated gene (NAG-1), a modulator of tumorigenesis, J Biochem Mol Biol, 39, 649

Bauskin, 2005, The propeptide mediates formation of stromal stores of PROMIC-1: Role in determining prostate cancer outcome, Cancer Res, 65, 2330, 10.1158/0008-5472.CAN-04-3827

Fairlie, 2000, Expression of a TGF-beta superfamily protein, macrophage inhibitory cytokine-1, in the yeast Pichia pastoris, Gene, 254, 67, 10.1016/S0378-1119(00)00295-X

Breit, 2011, The TGF-β superfamily cytokine, MIC-1/GDF15: A pleotrophic cytokine with roles in inflammation, cancer and metabolism, Growth Factors, 29, 187, 10.3109/08977194.2011.607137

Hromas, 1997, PLAB, a novel placental bone morphogenetic protein, Biochim Biophys Acta, 1354, 40, 10.1016/S0167-4781(97)00122-X

Soucek, 2010, Growth/differentiation factor-15 is an abundant cytokine in human seminal plasma, Hum Reprod, 25, 2962, 10.1093/humrep/deq264

Moore, 2000, The transforming growth factor-β superfamily cytokine macrophage inhibitory cytokine-1 is present in high concentrations in the serum of pregnant women, J Clin Endocrinol Metab, 85, 4781

Tong, 2004, Serum concentrations of macrophage inhibitory cytokine 1 (MIC 1) as a predictor of miscarriage, Lancet, 363, 129, 10.1016/S0140-6736(03)15265-8

Wiklund, 2010, Macrophage inhibitory cytokine-1 (MIC-1/GDF15): A new marker of all-cause mortality, Aging Cell, 9, 1057, 10.1111/j.1474-9726.2010.00629.x

Daniels, 2011, Growth-differentiation factor-15 is a robust, independent predictor of 11-year mortality risk in community-dwelling older adults: The Rancho Bernardo Study, Circulation, 123, 2101, 10.1161/CIRCULATIONAHA.110.979740

Basil, 2006, Common cancer biomarkers, Cancer Res, 66, 2953, 10.1158/0008-5472.CAN-05-3433

Mimeault, 2010, Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine-1 in cancer, J Cell Physiol, 224, 626, 10.1002/jcp.22196

Welsh, 2001, Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer, Cancer Res, 61, 5974

Buckhaults, 2001, Secreted and cell surface genes expressed in benign and malignant colorectal tumors, Cancer Res, 61, 6996

Koopmann, 2004, Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry, Clin Cancer Res, 10, 860, 10.1158/1078-0432.CCR-1167-3

Zhang, 2009, Expression of growth differentiation factor 15 is positively correlated with histopathological malignant grade and in vitro cell proliferation in oral squamous cell carcinoma, Oral Oncol, 45, 627, 10.1016/j.oraloncology.2008.07.017

Boyle, 2009, Macrophage inhibitory cytokine-1 is overexpressed in malignant melanoma and is associated with tumorigenicity, J Invest Dermatol, 129, 383, 10.1038/jid.2008.270

Park, 2010, Macrophage inhibitory cytokine-1 transactivates ErbB family receptors via the activation of Src in SK-BR-3 human breast cancer cells, BMB Rep, 43, 91, 10.5483/BMBRep.2010.43.2.091

Roth, 2010, GDF-15 contributes to proliferation and immune escape of malignant gliomas, Clin Cancer Res, 16, 3851, 10.1158/1078-0432.CCR-10-0705

Lee, 2003, Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system, Cancer Res, 63, 4648

Corre, 2007, Bone marrow mesenchymal stem cells are abnormal in multiple myeloma, Leukemia, 21, 1079, 10.1038/sj.leu.2404621

Li, 2000, Placental transforming growth factor-beta is a downstream mediator of the growth arrest and apoptotic response of tumor cells to DNA damage and p53 overexpression, J Biol Chem, 275, 20127, 10.1074/jbc.M909580199

Baek, 2006, Nonsteroidal anti-inflammatory drug-activated gene-1 over expression in transgenic mice suppresses intestinal neoplasia, Gastroenterology, 131, 1553, 10.1053/j.gastro.2006.09.015

Baek, 2002, Resveratrol enhances the expression of non-steroidal anti-inflammatory drug-activated gene (NAG-1) by increasing the expression of p53, Carcinogenesis, 23, 425, 10.1093/carcin/23.3.425

Baek, 2005, Cyclooxygenase inhibitors induce the expression of the tumor suppressor gene EGR-1, which results in the up-regulation of NAG-1, an antitumorigenic protein, Mol Pharmacol, 67, 356, 10.1124/mol.104.005108

Yamaguchi, 2004, Identification of nonsteroidal anti-inflammatory drug-activated gene (NAG-1) as a novel downstream target of phosphatidylinositol 3-kinase/AKT/GSK-3beta pathway, J Biol Chem, 279, 49617, 10.1074/jbc.M408796200

Corre, 2012, Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma, Cancer Res, 72, 1395, 10.1158/0008-5472.CAN-11-0188

Huang, 2007, Molecular alterations in prostate carcinomas that associate with in vivo exposure to chemotherapy: Identification of a cytoprotective mechanism involving growth differentiation factor 15, Clin Cancer Res, 13, 5825, 10.1158/1078-0432.CCR-07-1037

Subramaniam, 2003, Growth differentiation factor-15 prevents low potassium-induced cell death of cerebellar granule neurons by differential regulation of Akt and ERK pathways, J Biol Chem, 278, 8904, 10.1074/jbc.M210037200

Johnen, 2007, Tumor-induced anorexia and weight loss are mediated by the TGF-beta superfamily cytokine MIC-1, Nat Med, 13, 1333, 10.1038/nm1677

Kim, 2008, Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells, Carcinogenesis, 29, 704, 10.1093/carcin/bgn031

Xu, 2006, GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation, Circ Res, 98, 342, 10.1161/01.RES.0000202804.84885.d0

de Jager, 2011, Growth differentiation factor 15 deficiency protects against atherosclerosis by attenuating CCR2-mediated macrophage chemotaxis, J Exp Med, 208, 217, 10.1084/jem.20100370

Huh, 2010, Macrophage inhibitory cytokine-1 regulates melanoma vascular development, Am J Pathol, 176, 2948, 10.2353/ajpath.2010.090963

Albertoni, 2002, Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1, Oncogene, 21, 4212, 10.1038/sj.onc.1205610

Liu, 2003, Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells, Cancer Res, 63, 5034

Senapati, 2010, Overexpression of macrophage inhibitory cytokine-1 induces metastasis of human prostate cancer cells through the FAK-RhoA signaling pathway, Oncogene, 29, 1293, 10.1038/onc.2009.420

Wakchoure, 2009, Expression of macrophage inhibitory cytokine-1 in prostate cancer bone metastases induces osteoclast activation and weight loss, Prostate, 69, 652, 10.1002/pros.20913

Hinoi, 2012, Positive regulation of osteoclastic differentiation by growth differentiation factor 15 upregulated in osteocytic cells under hypoxia, J Bone Miner Res, 27, 938, 10.1002/jbmr.1538

Martin, 2011, The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma, Leukemia, 25, 1533, 10.1038/leu.2011.122

Brown, 2003, MIC-1 serum level and genotype: Associations with progress and prognosis of colorectal carcinoma, Clin Cancer Res, 9, 2642

Ding, 2009, Identification of macrophage inhibitory cytokine-1 in adipose tissue and its secretion as an adipokine by human adipocytes, Endocrinology, 150, 1688, 10.1210/en.2008-0952

Brown, 2009, Macrophage inhibitory cytokine 1: A new prognostic marker in prostate cancer, Clin Cancer Res, 15, 6658, 10.1158/1078-0432.CCR-08-3126

Koopmann, 2006, Serum markers in patients with resectable pancreatic adenocarcinoma: Macrophage inhibitory cytokine 1 versus CA19–9, Clin Cancer Res, 12, 442, 10.1158/1078-0432.CCR-05-0564

Staff, 2010, Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer, Gynecol Oncol, 118, 237, 10.1016/j.ygyno.2010.05.032

Staff, 2011, Elevated plasma growth differentiation factor-15 correlates with lymph node metastases and poor survival in endometrial cancer, Clin Cancer Res, 17, 4825, 10.1158/1078-0432.CCR-11-0715

Kluger, 2011, Plasma markers for identifying patients with metastatic melanoma, Clin Cancer Res, 17, 2417, 10.1158/1078-0432.CCR-10-2402

Tanno, 2007, High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin, Nat Med, 13, 1096, 10.1038/nm1629

Tamary, 2008, Elevated growth differentiation factor 15 expression in patients with congenital dyserythropoietic anemia type I, Blood, 112, 5241, 10.1182/blood-2008-06-165738

Ramirez, 2009, Growth differentiation factor 15 production is necessary for normal erythroid differentiation and is increased in refractory anaemia with ring-sideroblasts, Br J Haematol, 144, 251, 10.1111/j.1365-2141.2008.07441.x

Finkenstedt, 2009, Regulation of iron metabolism through GDF15 and hepcidin in pyruvate kinase deficiency, Br J Haematol, 144, 789, 10.1111/j.1365-2141.2008.07535.x

Bruns, 2012, Multiple myeloma-related deregulation of bone marrow-derived CD34+ hematopoietic stem and progenitor cells, Blood, 120, 2620, 10.1182/blood-2011-04-347484

Brown, 2002, Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: A nested case-control study, Lancet, 359, 2159, 10.1016/S0140-6736(02)09093-1

Kempf, 2007, Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure, J Am Coll Cardiol, 50, 1054, 10.1016/j.jacc.2007.04.091

Kempf, 2007, Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction, Eur Heart J, 28, 2858, 10.1093/eurheartj/ehm465

Wollert, 2007, Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome, Circulation, 115, 962, 10.1161/CIRCULATIONAHA.106.650846

Lankeit, 2008, Growth differentiation factor-15 for prognostic assessment of patients with acute pulmonary embolism, Am J Respir Crit Care Med, 177, 1018, 10.1164/rccm.200712-1786OC

Nickel, 2008, Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension, Am J Respir Crit Care Med, 178, 534, 10.1164/rccm.200802-235OC

Foley, 2009, Growth differentiation factor-15 predicts mortality and morbidity after cardiac resynchronization therapy, Eur Heart J, 30, 2749, 10.1093/eurheartj/ehp300

Norozi, 2011, Growth differentiation factor 15: An additional diagnostic tool for the risk stratification of developing heart failure in patients with operated congenital heart defects?, Am Heart J, 162, 131, 10.1016/j.ahj.2011.03.036

Wollert, 2012, Growth differentiation factor 15 in heart failure: An update, Curr Heart Fail Rep, 9, 337, 10.1007/s11897-012-0113-9

Johnen, 2012, Increased expression of the TGF-b superfamily cytokine MIC-1/GDF15 protects ApoE(−/−) mice from the development of atherosclerosis, Cardiovasc Pathol, 21, 499, 10.1016/j.carpath.2012.02.003

Bonaterra, 2012, Growth differentiation factor-15 deficiency inhibits atherosclerosis progression by regulating interleukin-6-dependent inflammatory response to vascular injury, J Am Heart Assoc, 1, e002550, 10.1161/JAHA.112.002550

Kempf, 2006, The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury, Circ Res, 98, 351, 10.1161/01.RES.0000202805.73038.48

Xu, 2011, Growth differentiation factor 15 in cardiovascular diseases: From bench to bedside, Biomarkers, 16, 466, 10.3109/1354750X.2011.580006

Brown, 2007, Serum macrophage inhibitory cytokine 1 in rheumatoid arthritis. A potential marker of erosive joint destruction, Arthritis Rheum, 56, 753, 10.1002/art.22410

Breit, 2012, Macrophage inhibitory cytokine-1 (MIC-1/GDF15) and mortality in end-stage renal disease, Nephrol Dial Transplant, 27, 70, 10.1093/ndt/gfr575

Hellemons, 2012, Growth-differentiation factor 15 predicts worsening of albuminuria in patients with type 2 diabetes, Diabetes Care, 35, 2340, 10.2337/dc12-0180

Mensching, 2012, Local substitution of GDF-15 improves axonal and sensory recovery after peripheral nerve injury, Cell Tissue Res, 350, 225, 10.1007/s00441-012-1493-6

Hsiao, 2000, Characterization of growth-differentiation factor 15, a transforming growth factor beta superfamily member induced following liver injury, Mol Cell Biol, 20, 3742, 10.1128/MCB.20.10.3742-3751.2000

Strelau, 2009, Progressive postnatal motoneuron loss in mice lacking GDF-15, J Neurosci, 29, 13640, 10.1523/JNEUROSCI.1133-09.2009